Stock Track | Relay Therapeutics Soars 5.57% Intraday on Strong Q4 Earnings Beat and Analyst Optimism

Stock Track

Feb 27

Relay Therapeutics' stock surged 5.57% during intraday trading on Friday, extending gains from earlier sessions.

The clinical-stage precision medicine company's strong performance follows the release of its fourth quarter 2025 financial results, which significantly exceeded analyst expectations. Relay Therapeutics reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million, and posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss.

Investor sentiment was further bolstered by the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program. Additionally, analyst optimism contributed to the positive momentum, with Oppenheimer reiterating a Buy rating on the stock today with a price target of $14.00.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1118860865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118860865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118860865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118860865","market":"us","top_or_hot":-1,"title":"Stock Track | Relay Therapeutics Soars 5.57% Intraday on Strong Q4 Earnings Beat and Analyst Optimism","media":"Stock Track","content":"<p>Relay Therapeutics' stock surged 5.57% during intraday trading on Friday, extending gains from earlier sessions.</p><p>The clinical-stage precision medicine company's strong performance follows the release of its fourth quarter 2025 financial results, which significantly exceeded analyst expectations. Relay Therapeutics reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million, and posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss.</p><p>Investor sentiment was further bolstered by the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program. Additionally, analyst optimism contributed to the positive momentum, with Oppenheimer reiterating a Buy rating on the stock today with a price target of $14.00.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Relay Therapeutics Soars 5.57% Intraday on Strong Q4 Earnings Beat and Analyst Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Relay Therapeutics Soars 5.57% Intraday on Strong Q4 Earnings Beat and Analyst Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Relay Therapeutics' stock surged 5.57% during intraday trading on Friday, extending gains from earlier sessions.</p><p>The clinical-stage precision medicine company's strong performance follows the release of its fourth quarter 2025 financial results, which significantly exceeded analyst expectations. Relay Therapeutics reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million, and posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss.</p><p>Investor sentiment was further bolstered by the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program. Additionally, analyst optimism contributed to the positive momentum, with Oppenheimer reiterating a Buy rating on the stock today with a price target of $14.00.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"","article_id":"1118860865","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118860865","pubTimestamp":1772202829,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Relay Therapeutics' stock surged 5.57% during intraday trading on Friday, extending gains from earlier sessions.The clinical-stage precision medicine company's strong performance follows the release...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics"},"translate_title":"个股追踪|Relay Therapeutics盘中飙升5.57%，因第四季度盈利强劲增长和分析师乐观情绪","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLAY":1},"content_text":"Relay Therapeutics' stock surged 5.57% during intraday trading on Friday, extending gains from earlier sessions.The clinical-stage precision medicine company's strong performance follows the release of its fourth quarter 2025 financial results, which significantly exceeded analyst expectations. Relay Therapeutics reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million, and posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss.Investor sentiment was further bolstered by the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program. Additionally, analyst optimism contributed to the positive momentum, with Oppenheimer reiterating a Buy rating on the stock today with a price target of $14.00.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}